Comparative analysis of essential drug lists in four central asian republics
Download
1 / 21

Comparative analysis of essential drug lists in four Central Asian Republics. - PowerPoint PPT Presentation


Comparative analysis of essential drug lists in four Central Asian Republics. Aziz Jafarov / Richard Laing. Countries. K a z a k h s t a n K y r g y z s t a n T a j i k i s t a n U z b e k i s t a n. Population and health financing in Kazakhstan, Kyrgyzstan, Tajikistan and Uzbekistan.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha

Download Presentation

Comparative analysis of essential drug lists in four Central Asian Republics.

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Comparative analysis of essential drug lists in four central asian republics l.jpg

Comparative analysis of essential drug lists in four Central Asian Republics.

Aziz Jafarov / Richard Laing


Countries l.jpg

Countries

  • K a z a k h s t a n

  • K y r g y z s t a n

  • T a j i k i s t a n

  • U z b e k i s t a n


Population and health financing in kazakhstan kyrgyzstan tajikistan and uzbekistan l.jpg

Population and health financing in Kazakhstan, Kyrgyzstan, Tajikistan and Uzbekistan


Method l.jpg

Method

  • Сompares the existing Essential Drug Lists of Kazakhstan, Kyrgyzstan, Uzbekistan, and Tajikistan with the WHO Model EDL List from 1999.

  • The 2002 WHO Model list is the same as the 1999 list, except for the additional Anti Retro Viral (ARVs) and anti malarial drugs.

  • For the purpose of this analysis, we have combined core and complementary drugs into a single master list.

  • For this paper a comparative table has been developed and the 1999 WHO Model EDL was taken as the standard.


Method5 l.jpg

Method

Drugs on national EDLs were classified as being:

  • 1) on the WHO Model EDL

  • 2) From the same therapeutic group

  • 3) Not included on the WHO Model List.

    Based on the spreadsheet, summary tables were developed for all the EDLs and the WHO Model List and some of the therapeutic groups in order to compare with the national and the WHO list.


General results comparative table of edls of car and who model list summary l.jpg

General resultsComparative table of EDLs of CAR and WHO Model ListSUMMARY


General results l.jpg

General results


Forms and dosage erythromycin in who kazakhstan kyrgyzstan and uzbekistan edls l.jpg

Forms and dosageErythromycin in WHO, Kazakhstan, Kyrgyzstan and Uzbekistan EDLs.


Forms and doses l.jpg

Forms and doses


Forms and doses10 l.jpg

Forms and doses


Form and doses l.jpg

Form and doses


Cardiovascular drugs l.jpg

Cardiovascular drugs


Cardiovascular drugs13 l.jpg

Cardiovascular drugs


Gastrointestinal drugs l.jpg

Gastrointestinal drugs


Drugs affecting the blood blood products and plasma l.jpg

Drugs affecting the blood, blood products and plasma


Recommendation l.jpg

Recommendation

  • Design and conduct in-depth studies to evaluate the selection process in each country of the region and introduce and update the selection process according to the latest developments

  • Organize meetings at regional level on the EDL concept and selection process


Recommendation17 l.jpg

Recommendation

  • Intensify collaboration with the WHO to select evidence-based medicines. WHO is the key organization in developing the EDL concept, and should continue to update countries on the changes made while revising the model EDL.

  • Reduce the number of forms and doses

  • Exclude the column of brand names as alternatives for generic names

  • Any information, which might possibly lead to misinterpretation, should be excluded from the list;


Recommendation18 l.jpg

Recommendation

  • Assign the essential drugs by level of care: Primary, Secondary and Tertiary;

  • Create incentives for the private sector to import in generic essential drugs

  • Waive all duties for essential drugs and incentives for medical professionals to prescribe essential drugs

  • Assure registration of all the EDL drugs

  • Design brochures and regular newsletters on EDL and distribute them to medical professionals


Conclusion l.jpg

Conclusion

  • There has been a significant effort by Kazakhstan, Kyrgyzstan, Tajikistan and Uzbekistan to implement the Essential Drug Concept. All of the four former Soviet Central Asian countries developed and revised their EDLs.

  • The total number of drugs included in the national lists is reasonable, except for the listing of brand names in Tajikistan and Kazakhstan EDLs.

  • Local institutions contributed to the process of the development and revision of the lists, and there is knowledge and interest in the ED concept.


Conclusion20 l.jpg

Conclusion

  • The number of essential drugs among the four countries, the drugs selected for the national lists, and the excessive number of forms and doses for Kyrgyzstan and Uzbekistan make the lists controversial.

  • Inclusion of the brand names in a separate column in Kazakhstan and Tajikistan EDLs creates room for misinterpretation and for bad procurement practices.

  • The EDLs of Kazakhstan, Kyrgyzstan, Tajikistan and Uzbekistan are very different. At least some of their selected drugs and the selection process itself require radical revision.


Slide21 l.jpg

  • THANK YOU!


ad
  • Login